News | September 02, 2010

Radiofrequency Ablation for AF May Cause Esophageal Injury

September 2, 2010 – New research released this week is the first to find both anatomical and procedural considerations that can lead to the creation of esophageal ulcerations (ESUL) after radiofrequency ablation of atrial fibrillation (AF). According to a study published in the September issue of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, patients at high risk for esophageal injury can be identified based on pre-acquired multi-slice computed tomography. The study is the largest to provide serial endoscopy data on the esophagus after radiofrequency ablation.

The study population consisted of 275 patients admitted to the Elisabethinen University Teaching Hospital Linz for pulmonary vein (PV) isolation from September 2007 to June 2009. A standardized ablation approach using a 25-W energy maximum at the posterior left atrial (LA) wall without esophagus visualization, temperature monitoring or intracardiac ultrasound was performed. All patients were screened for evidence of the development of ESUL 24 hours after RFA. ESUL did not develop in any patient who had PV isolation alone.

Study analysis revealed that the greatest anatomical risk factor for the development of ESUL was a small LA-to-esophageal distance. Within the study population, the total risk of ulcers developing was 2.2 percent. Wall legions were classified as ESUL created by radiofrequency ablation by means of localization and endosonographic appearance. Anatomical factors included in the multivariate model were LA-to-esophageal distance, type of AF and additional LA linear lesions. LA-to-esophageal distance was the only independent predictor of the development of ESUL.

“It has been speculated that esophageal ulcerations can lead to atrioesophageal fistula, which is a rare but life-threatening complication of AF,” said lead author Martin Martinek, M.D., Public Hospital Elisabethinen, Academic Teaching Hospital of the University of Innsbruck and Graz in Austria. “Our study aimed to discover risk factors that can lead to injuries of the esophagus due to radiofrequency ablation. In doing so, we may better identify high-risk patients to determine the most appropriate course of action for RFA and its followup.”

For more information: www.heartrhythmjournal.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init